GSK3 polypeptides

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3alpha and GSK3beta polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-...

Full description

Saved in:
Bibliographic Details
Main Authors NGUYEN STEVE H, MEDINA-SELBY ANGELICA, HARRISON STEPHEN D, CALDERON-CACIA MARIA, COIT DORIS G, ZHONG ZIYANG, FANG ERIC Y, HALL JOHN A
Format Patent
LanguageEnglish
Published 27.03.2007
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3alpha and GSK3beta polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
Bibliography:Application Number: US20030733816